Harris Williams Advises GI Partners on its Acquisition of California Cryobank and Cord Blood Registry

August 7, 2018

Harris Williams, a preeminent middle market investment bank focused on the advisory needs of clients worldwide for more than 25 years, announces that it advised GI Partners on its acquisition of California Cryobank and Cord Blood Registry® (CBR®). GI Partners simultaneously acquired and combined both companies. The transactions were led by Andy Dixon of Harris Williams’ Healthcare & Life Sciences (HCLS) Group.

“We are pleased to have advised GI Partners in bringing together two industry leaders with highly complementary service offerings. The transaction is indicative of the high level of investor interest in the women’s health, fertility and stem cell sectors,” said Andy Dixon, a managing director at Harris Williams.

California Cryobank provides frozen donor sperm and egg services, reproductive tissue storage and cord blood/tissue banking (through FamilyCord) and is registered with the FDA, accredited by the AATB and AABB, and licensed by the states of California and New York.

CBR® is one of the world's largest newborn stem cell companies. Founded in 1992, CBR is entrusted by parents with storing samples from more than 600,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today.

GI Partners is a private investment firm based in San Francisco. The firm has raised $16 billion in capital from leading institutional investors across the globe. GI Partners' private equity team focuses on investments in the IT infrastructure, healthcare, software and services sectors. 

Harris Williams (www.harriswilliams.com), a subsidiary of the PNC Financial Services Group, Inc. (NYSE:PNC), is a preeminent middle market investment bank focused on the advisory needs of clients worldwide.  The firm has deep industry knowledge, global transaction expertise and an unwavering commitment to excellence. Harris Williams provides sell-side and acquisition advisory, restructuring advisory, board advisory, private placements and capital markets advisory services.

Harris Williams’ HCLS Group has experience across a broad range of sectors, including medical devices, products and distribution; multi-site and retail healthcare providers; alternate site care; healthcare IT; managed care and cost containment services; outsourced clinical services; and outsourced pharma services.  For more information on the HCLS Group and other recent transactions, visit the HCLS Group’s section of the Harris Williams website.

Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams & Co. Ltd, which is a private limited company incorporated under English law with its registered office at 5th Floor, 6 St. Andrew Street, London EC4A 3AE, UK, registered with the Registrar of Companies for England and Wales (registration number 07078852). Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams is a trade name under which Harris Williams LLC and Harris Williams & Co. Ltd conduct business.